MBT-2 Orthotopic Mouse Model Service for Bladder Cancer

The MBT-2 orthotopic mouse model recapitulates the natural bladder microenvironment with remarkable fidelity, serving as a robust syngeneic platform for evaluating intravesical therapies, immune checkpoint inhibitors, and novel antitumor agents in a physiologically relevant setting. At Alfa Cytology, we engineer this model with surgical precision and stringent quality controls—delivering reproducible tumor establishment, real-time growth monitoring via multimodal imaging, and customizable study designs that align with your compound’s preclinical development roadmap.

Overview of MBT-2 Orthotopic Mouse Model for Bladder Cancer

The MBT-2 cell line was originally established from a transitional cell carcinoma arising in the bladder epithelium of a C3H/He mouse following chronic exposure to FANFT (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide), a potent nitrofuran carcinogen. As a murine-derived tumor line, MBT-2 preserves full histocompatibility with syngeneic C3H/He hosts, making it uniquely suited for immunocompetent preclinical studies. The cells exhibit epithelial morphology, express cytokeratins and uroplakins consistent with urothelial origin, and carry hallmark driver mutations including activating Hras (G12V) and Trp53 alterations. Their polyploid karyotype—ranging from 4N to 16N—reflects the genomic instability frequently observed in advanced human bladder malignancies.

Fig 1. Surgical orthotopic inoculation of bladder cancer cells (MBT-2 cells) into a C3H/HeNCrl mouse. (Noh, Ji-In, et al., 2023)

When implanted orthotopically into the bladder wall or instilled intravesically following mucosal preconditioning, MBT-2 cells establish invasive, poorly differentiated carcinomas within two to three weeks. The model supports both intraluminal and intramural tumor growth patterns, enabling evaluation of intravesical drug delivery, systemic chemotherapy, and immunotherapy regimens. Notably, MBT-2 tumors upregulate VEGF and MMP-9, providing a relevant backdrop for assessing anti-angiogenic and anti-metastatic strategies. Tumor burden can be tracked longitudinally through high-frequency micro-ultrasound, MRI, or bioluminescence imaging when reporter-modified variants are employed.

Cell Line Information: MBT-2

MBT-2 (Mouse Bladder Tumor-2) is a chemically induced murine transitional cell carcinoma line that has been extensively characterized and widely adopted in bladder cancer research. Below is a comprehensive summary of its biological and technical attributes.

Our Services

Alfa Cytology specializes in the construction and deployment of the MBT-2 orthotopic bladder cancer model as part of its comprehensive preclinical oncology portfolio. Our in-house surgical team performs both transurethral intravesical instillation and open intramural injection protocols under full IACUC oversight, with each study batch subjected to mycoplasma testing, cell viability verification, and histopathological confirmation of tumor phenotype. Whether your program requires standard tumor growth monitoring, combination therapy assessment, or reporter-engineered variants for bioluminescence tracking, we tailor the experimental design to your therapeutic modality and deliver milestone-ready data packages.

Workflow of MBT-2 Orthotopic Mouse Model Construction

Construction of the MBT-2 orthotopic bladder tumor model follows a rigorously standardized surgical and cell-handling pipeline. Two principal routes are employed—transurethral intravesical instillation and open surgical intramural injection—selected based on study objectives, tumor growth kinetics, and the need for intravesical versus systemic drug access. The entire procedure is conducted under aseptic conditions with continuous physiological monitoring.

1. Cell Preparation and Quality Control: MBT-2 cells are expanded in RPMI 1640 complete medium and harvested during exponential growth phase. A single-cell suspension is prepared to minimize clumping, and viability is confirmed by trypan blue exclusion (>80% viability required). Mycoplasma PCR testing is performed on each batch prior to implantation.
2. Host Mouse Preparation: Female C3H/He mice, 6–8 weeks of age, are acclimatized for at least one week. On the day of surgery, mice are weighed and anesthetized with an intraperitoneal cocktail (e.g., ketamine/medetomidine or pentobarbital sodium). Ophthalmic ointment is applied, and body temperature is maintained on a heated pad.
3. Bladder Emptying and Preconditioning (Transurethral Route): Urine is gently evacuated by lower abdominal pressure. A 24-gauge IV catheter (stylet removed) is lubricated and advanced transurethrally into the bladder. Fifty microliters of poly-L-lysine (PLL) or trypsin solution is instilled slowly (10 µL per 20 s) to precondition the urothelial glycosaminoglycan layer, enhancing tumor cell adhesion. The catheter is stoppered for 20 minutes.
4. Tumor Cell Instillation or Injection: For intravesical delivery, 1×10⁶ to 2×10⁶ MBT-2 cells in 50 µL PBS or serum-free medium are instilled slowly through the catheter, which is then stoppered for 60 minutes to allow cell attachment. For the open surgical route, a 1-cm midline abdominal incision is made, the bladder is exteriorized, urine is aspirated, and 2.5×10⁵ to 5×10⁵ cells are injected intramurally using a 31-gauge needle parallel to the muscle layer.
5. Post-Procedure Management: Following transurethral instillation, the bladder is evacuated and mice receive a reversal agent (e.g., atipamezole). After open surgery, the bladder is returned to the cavity, the abdominal wall is sutured in layers, and mice are deprived of water for 16 hours to reduce post-surgical urination and cell loss. Analgesia is administered per institutional guidelines.
6. Tumor Monitoring and Endpoint Assessment: Tumor growth is tracked longitudinally via high-frequency micro-ultrasound, MRI, or bioluminescence imaging (for luciferase-expressing MBT-2 variants). Imaging sessions are typically scheduled every 3–7 days. At study endpoint, bladders are harvested, weighed, and subjected to H&E and IHC staining for histopathological validation.

Fig 2. MBT-2 Orthotopic Mouse Model construction workflow.

Case Study-MBT-2 Orthotopic Mouse Model Development

In a representative preclinical engagement, Alfa Cytology established the MBT-2 orthotopic model to evaluate the intravesical efficacy of a novel therapeutic candidate targeting bladder cancer progression. Following surgical implantation, tumors were monitored weekly via high-frequency ultrasound, with treatment initiation timed to achieve a mean tumor volume of approximately 50–100 mm³. Animals were randomized into vehicle control and treatment cohorts, with body weight and general health status recorded throughout the dosing period. At study termination, bladders were excised for gravimetric analysis and histopathological examination, including H&E staining and IHC profiling of proliferation and apoptosis markers. The resulting dataset provided quantitative evidence of tumor growth inhibition, supported by correlative biomarker changes, and informed the sponsor’s decision to advance the compound into subsequent preclinical safety studies.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your MBT-2 orthotopic bladder cancer study means gaining access to a technically refined model platform backed by experienced surgical scientists, rigorous quality assurance, and flexible study architectures.

• Surgical Precision: Our veterinary surgeons are trained in both transurethral and open orthotopic techniques, achieving high tumor take rates with minimal perioperative mortality.
• Immunocompetent Syngeneic Platform: The MBT-2/C3H/He system preserves a functional immune microenvironment, enabling robust evaluation of immuno-oncology agents and combination regimens.
• Multimodal Imaging Integration: We offer real-time tumor tracking via micro-ultrasound, MRI, and bioluminescence imaging, reducing cohort sizes and refining humane endpoints.
• Customizable Study Designs: From single-agent dose-response curves to complex combination schedules and intravesical delivery optimization, protocols are adapted to your compound’s mechanism of action.
• Regulatory-Ready Documentation: All studies are conducted under IACUC-approved protocols with comprehensive histopathology, biomarker analysis, and GLP-compatible data reporting.
• Dedicated Project Management: Each client is assigned a scientific project manager who provides weekly progress updates, troubleshoots technical issues, and ensures milestone alignment.

Contact Us

Ready to advance your bladder cancer therapeutic program with a validated MBT-2 orthotopic model? Reach out to us today to discuss your study requirements, receive a customized proposal, and explore how Alfa Cytology's preclinical expertise can accelerate your path from candidate selection to IND-enabling data.

Our scientific team is available to review your protocol, recommend optimal endpoints, and provide a detailed timeline and quotation tailored to your research objectives.

For research use only. Not intended for any clinical use.